The US biosimilar market expands with new denosumab options, enhancing treatment for patients with osteoporosis and ...

Novo Nordisk NVO announced that it has submitted a regulatory application to the European Medicines Agency (EMA) seeking ...

The hot flashes and night sweats that plague breast cancer survivors during years-long hormone-suppressing therapy are eased ...

Johnson & Johnson (NYSE:JNJ) is one of the 10 Best Non-Tech Stocks to Buy and Hold For 3 Years. On July 3, Janssen-Cilag, a ...

Novo Nordisk seeks EMA approval for 7.2 mg Wegovy dose after trials show 21% weight loss in people with obesity and type 2 diabetes.

Novo Nordisk submits a higher 7.2 mg dose of Wegovy for EMA approval, backed by trials showing 21% weight loss in obesity and ...

Denmark's Novo Nordisk said on Tuesday it had submitted a new, higher dose of its obesity treatment Wegovy to the European ...

Novo Nordisk has submitted a new, higher dose of its obesity treatment, Wegovy, for approval to the European Medicines Agency ...

MPS-I is a rare, inherited neurometabolic disease caused by a deficiency of the alpha-L-iduronidase (IDUA) lysosomal enzyme resulting in the accumulation of glycosaminoglycans (GAGs) in multiple ...

The EC granted conditional approval based on activity seen in a subset of IHC 3+ HER2-positive advanced biliary tract cancer patients in a Phase II trial.